Anthony Philippakis
Direktor/Vorstandsmitglied bei Rare-X
Profil
Anthony Philippakis was the founder of Verve Therapeutics, Inc. (founded in 2018) where he held the title of Director from 2018 to 2021.
He is currently a Director at Rare-X and a General Partner at GV Management Co. LLC (since 2012).
Previously, he was a Director at Decibel Therapeutics, Inc. from 2018 to 2021.
Dr. Philippakis has a graduate degree from the University of Cambridge (conferred in 2000), an undergraduate degree from Yale University (conferred in 1998), and a doctorate from Harvard Medical School (conferred in 2009).
Aktive Positionen von Anthony Philippakis
| Unternehmen | Position | Beginn |
|---|---|---|
GV Management Co. LLC
 GV Management Co. LLC Investment ManagersFinance GV Management Co LLC (Google Ventures) is a venture capital firm, a subsidiary of Google LLC founded in 2009 by Bill Maris. The firm is headquartered in Mountain View, California with an additional office in San Francisco, Boston, New York and London. | Private Equity Investor | 01.04.2012 |
Rare-X
 Rare-X Packaged SoftwareTechnology Services Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Anthony Philippakis
| Unternehmen | Position | Ende |
|---|---|---|
| VERVE THERAPEUTICS, INC. | Gründer | 01.05.2021 |
| DECIBEL THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.01.2021 |
Ausbildung von Anthony Philippakis
| Yale University | Undergraduate Degree |
| Harvard Medical School | Doctorate Degree |
| University of Cambridge | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| DECIBEL THERAPEUTICS, INC. | Health Technology |
| VERVE THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
GV Management Co. LLC
GV Management Co. LLC Investment ManagersFinance GV Management Co LLC (Google Ventures) is a venture capital firm, a subsidiary of Google LLC founded in 2009 by Bill Maris. The firm is headquartered in Mountain View, California with an additional office in San Francisco, Boston, New York and London. | Finance |
Rare-X
Rare-X Packaged SoftwareTechnology Services Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023. | Technology Services |
